iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Equities research analysts at Leerink Partnrs lowered their Q2 2025 earnings per share (EPS) estimates for shares of iTeos Therapeutics in a research note issued to investors on Wednesday, May 28th. Leerink Partnrs analyst D. Graybosch now anticipates that the company will post earnings per share of ($0.84) for the quarter, down from their prior forecast of ($0.62). Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for iTeos Therapeutics' current full-year earnings is ($3.49) per share. Leerink Partnrs also issued estimates for iTeos Therapeutics' Q3 2025 earnings at ($0.67) EPS and FY2025 earnings at ($2.31) EPS.
Other equities research analysts have also issued research reports about the company. Leerink Partners reissued a "market perform" rating and set a $9.00 target price (down previously from $47.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. HC Wainwright downgraded shares of iTeos Therapeutics from a "buy" rating to a "neutral" rating in a research report on Wednesday, May 14th. JPMorgan Chase & Co. downgraded shares of iTeos Therapeutics from an "overweight" rating to a "neutral" rating and reduced their price objective for the stock from $15.00 to $8.00 in a research report on Tuesday, May 13th. Wells Fargo & Company reiterated an "equal weight" rating and set a $12.00 price target (down from $13.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 28th. Finally, Wedbush lowered shares of iTeos Therapeutics from an "outperform" rating to a "neutral" rating and lifted their price target for the stock from $10.00 to $12.00 in a research note on Wednesday, May 28th. Six investment analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat.com, iTeos Therapeutics currently has an average rating of "Hold" and a consensus target price of $15.86.
Get Our Latest Stock Report on iTeos Therapeutics
iTeos Therapeutics Stock Down 0.2%
iTeos Therapeutics stock traded down $0.02 during midday trading on Monday, reaching $10.18. The company's stock had a trading volume of 1,099,697 shares, compared to its average volume of 654,838. iTeos Therapeutics has a fifty-two week low of $4.80 and a fifty-two week high of $18.13. The company has a market cap of $389.63 million, a P/E ratio of -3.23 and a beta of 1.39. The business has a 50-day simple moving average of $7.20 and a 200-day simple moving average of $7.44.
iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last issued its quarterly earnings results on Monday, April 28th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.94) by $0.14.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the business. Strs Ohio acquired a new position in shares of iTeos Therapeutics during the 1st quarter worth $31,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in iTeos Therapeutics during the fourth quarter worth about $42,000. CWM LLC grew its position in iTeos Therapeutics by 428.7% during the first quarter. CWM LLC now owns 8,554 shares of the company's stock worth $51,000 after buying an additional 6,936 shares during the period. Paloma Partners Management Co acquired a new stake in shares of iTeos Therapeutics in the 1st quarter worth approximately $65,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of iTeos Therapeutics in the 1st quarter worth approximately $67,000. Institutional investors and hedge funds own 97.16% of the company's stock.
Insider Buying and Selling at iTeos Therapeutics
In other iTeos Therapeutics news, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the business's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total value of $5,079,339.46. Following the transaction, the insider now directly owns 2,108,594 shares of the company's stock, valued at approximately $16,995,267.64. The trade was a 23.01% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Ansbert Gadicke sold 1,031,931 shares of the business's stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total transaction of $8,317,363.86. Following the transaction, the insider now owns 3,452,797 shares in the company, valued at approximately $27,829,543.82. This trade represents a 23.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 12.50% of the stock is currently owned by company insiders.
About iTeos Therapeutics
(
Get Free Report)
iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
See Also
Before you consider iTeos Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iTeos Therapeutics wasn't on the list.
While iTeos Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
